Rebound Science

Deep dive · Metabolic science

Retatrutide research: what the trials have actually shown

Retatrutide is the most discussed investigational metabolic drug of the past few years, and almost none of that discussion cites the studies. This is a long read through the published retatrutide research — the phase 1 and phase 2 trials, the mechanism they were designed to test, the safety signals, the phase 3 programme still running, and the questions the data cannot yet answer.

Educational reference only. Retatrutide is an investigational drug available lawfully only through clinical trials. Nothing here is medical advice, a dosing protocol, or an endorsement of any product, supplier or "research" listing.

A scientist examining a sample vial in a research laboratory

The retatrutide research in brief

Retatrutide, development code LY3437943, is an investigational single-molecule agonist of three receptors: GLP-1, GIP and glucagon. It is being developed by Eli Lilly and has moved through phase 1 and phase 2 studies published in peer-reviewed journals, with a phase 3 programme underway. It is not approved by any regulator.

If you strip the published literature down to its findings, four claims are reasonably well supported by the current evidence, and one important caveat qualifies all of them.

  • Mean body weight reductions of roughly 24 percent at 48 weeks at the highest studied doses in adults with obesity, against about 2 percent on placebo.
  • Substantial HbA1c reductions in adults with type 2 diabetes, alongside weight loss.
  • Large reductions in liver fat content in participants with metabolic dysfunction-associated steatotic liver disease, with a high proportion reaching normal levels.
  • A tolerability profile dominated by dose-related gastrointestinal effects, plus a dose-dependent rise in heart rate.

The caveat: every one of those findings comes from early-phase trials designed to find dose and signal, not to establish long-term benefit or safety. Phase 2 results in metabolic medicine have a long history of shrinking in phase 3.

The mechanism the research was built to test

The scientific question behind retatrutide is whether adding glucagon receptor activation to dual incretin agonism increases energy expenditure enough to push weight loss past what appetite suppression alone achieves — without the glucose penalty glucagon would normally cause.

  • GLP-1 receptor. Glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, central appetite reduction. The pathway covered in our GLP-1 guide.
  • GIP receptor. The second incretin arm. Dual GLP-1/GIP agonism outperformed GLP-1 alone in trials of tirzepatide, though the mechanistic explanation is still argued over.
  • Glucagon receptor. Increases resting energy expenditure and mobilises hepatic fat. In isolation it raises blood glucose; the design bet is that incretin activity more than offsets that.

That is why researchers watched glucose handling and liver endpoints so closely in the published trials. Those were the pre-specified places where the glucagon arm would either prove its value or show its cost.

Phase 1 research

The first-in-human work established pharmacokinetics compatible with once-weekly dosing and produced the early signal that drove the programme forward: meaningful weight reduction within 12 weeks in participants with obesity, and glucose-lowering in participants with type 2 diabetes, with gastrointestinal adverse events concentrated during escalation.

Phase 1 studies are small and short. Their function in this story is narrow — they showed the molecule was tolerable enough at escalating doses to justify a phase 2 programme, and they shaped the escalation schedules used later.

Phase 2 research in obesity

The 48-week randomized, double-blind, placebo-controlled trial in adults with obesity is the study most retatrutide coverage is actually referring to. Participants were randomised across several dose arms and placebo, with escalation schedules varying by arm.

The result that drew attention was not only the magnitude — mean reductions near 24 percent at the highest doses — but the shape of the curve. Weight was still falling at week 48 in the higher-dose groups, with no clear plateau. In a field where weight curves typically flatten well before a year, that is genuinely unusual.

Read carefully, though, the curve is a hypothesis rather than a conclusion. A trial that ends before a plateau cannot tell you where the plateau is, and a 48-week window cannot tell you whether the trajectory is sustainable or tolerable across years.

Get the weekly research dispatch

One email. New peer-reviewed research, distilled. No spam, unsubscribe in one click.

Phase 2 research in type 2 diabetes

A parallel phase 2 trial studied adults with type 2 diabetes. HbA1c fell substantially across dose groups, with a large proportion of participants reaching target glycemic thresholds, and weight loss occurred alongside it.

This trial matters for the mechanism argument more than for the headlines. Glucagon receptor agonism could plausibly have worsened glycemic control; in the published data it did not. That is a meaningful piece of evidence in favour of the triple-agonist rationale, within the limits of a phase 2 sample.

Liver fat research

A sub-study in participants with metabolic dysfunction-associated steatotic liver disease reported large relative reductions in liver fat content measured by imaging, with most participants in the higher-dose arms achieving normal liver fat levels.

The honest framing: liver fat content is a surrogate endpoint. Reducing it is encouraging and biologically coherent with glucagon-driven hepatic fat mobilisation, but it is not the same as demonstrating reduced progression to fibrosis, cirrhosis or liver-related events. Those require longer trials with histological or clinical endpoints.

The phase 3 programme

The phase 3 programme spans obesity, obesity with knee osteoarthritis, obesity with obstructive sleep apnea, and cardiovascular outcomes in people with obesity and established cardiovascular disease. These are the trials that will determine whether retatrutide becomes a medicine and, if so, on what terms.

Two things are worth watching when those results publish. First, whether the phase 2 weight effect holds at scale, in broader populations, over longer periods. Second, whether the drug shows benefit on outcomes that matter to patients — events, function, symptoms — rather than on the surrogate measures that dominate the current evidence base.

Retatrutide research compared with other agonists

The comparison people want is a ranking. The literature does not support one cleanly, because cross-trial comparison ignores differences in population, duration, escalation and design. What can be said is roughly this: semaglutide's obesity trial reported mean reductions around 15 percent, tirzepatide's around 20 to 22 percent at the top dose, and retatrutide's phase 2 figure sits above both.

The asymmetry that matters is evidence maturity, not effect size. Semaglutide and tirzepatide have completed phase 3 programmes, regulatory review and — for semaglutide — a cardiovascular outcomes trial. Retatrutide has none of that. A bigger number from a smaller, shorter study is a weaker claim, not a stronger one.

Safety signals in the published data

  • Gastrointestinal effects. Nausea, vomiting, diarrhea and constipation were the most common adverse events, dose-related and concentrated during escalation — the familiar pattern for this drug class.
  • Heart rate. Dose-dependent increases were reported, appearing to peak partway through the trials and then decline. Whether that has consequences over years is unknown, and it is one reason the cardiovascular outcomes trial matters.
  • Glucose handling. Monitored closely because of the glucagon arm. Glycemic control improved overall in the published trials.
  • Lean mass. As with any agent producing very large weight loss, part of the loss is lean tissue. How much, and how best to limit it, remains unresolved across this whole drug class.

Limitations of the current evidence

  • Phase 2 sample sizes are not powered to detect uncommon harms.
  • Roughly one year of follow-up says nothing about multi-year use, which is how these drugs are used in practice.
  • Surrogate endpoints dominate: weight, HbA1c, liver fat. Hard outcomes are still being studied.
  • Discontinuation is barely characterised. With related agents, regain after stopping has been substantial.
  • Trial participants are selected and supervised, with pharmaceutical-grade product and structured escalation. None of that describes unsupervised use.

How to read the retatrutide literature yourself

If you want to evaluate the research rather than the commentary about it, a few habits do most of the work.

  • Check the phase. Phase 1 is safety and pharmacokinetics, phase 2 is dose and signal, phase 3 is proof. Headlines routinely blur them.
  • Find the endpoint. Ask whether the result is a surrogate measure or an outcome someone would notice in their life.
  • Read the comparator. Against placebo, against lifestyle intervention, or against an active drug? The answer changes what the number means.
  • Note the completion rate. Large dropouts in high-dose arms can flatter the results of everyone who stayed.
  • Separate the trial from the substance. A published result describes a supervised trial with a characterised compound, not whatever is in an unregulated vial.

Our peptides guide covers the general version of this: how peptide research is structured and where its weak points usually sit.

A large share of searches around retatrutide research are really searches about buying it — whether it is legal to buy "for research", where to get it, how to handle it. It is worth stating the position plainly.

Retatrutide is an investigational drug. The only lawful route to receiving it is participation in a clinical trial. Material sold online with research-use labelling sits outside the regulated supply chain: not manufactured to pharmaceutical standards, not verified for identity, purity or sterility, and not lawfully intended for human use. The FDA has repeatedly warned about compounded and counterfeit products across this drug class.

We do not publish sourcing, reconstitution or dosing information for retatrutide, and nothing on this page should be read as suggesting any use outside a trial. If you want to follow the science, follow the trials.

Common questions about retatrutide research

What does the retatrutide research show so far?

Published phase 1 and phase 2 trials report large reductions in body weight, HbA1c and liver fat, with weight still declining at the end of the 48-week obesity study. All of it is early-phase evidence in moderate numbers of participants.

Is there any phase 3 retatrutide data yet?

The TRIUMPH phase 3 programme is running across obesity, knee osteoarthritis with obesity, obstructive sleep apnea and cardiovascular outcomes, but the results that define approval are not published yet.

How does retatrutide research compare to tirzepatide and semaglutide research?

Retatrutide's phase 2 weight reduction sits above the phase 3 results reported for tirzepatide and semaglutide, but those two have completed far larger and longer programmes. Comparing a phase 2 number to a phase 3 number overstates what is known.

Is retatrutide legal to buy for research?

Retatrutide is an investigational drug, and the only lawful route to receiving it is enrolment in a clinical trial. Material sold online as a research chemical is outside the regulated supply chain, unverified for identity and purity, and not intended or safe for human use. We do not publish sourcing or dosing information.

What is the biggest weakness in the current evidence?

Duration and endpoints. Roughly one year of data on surrogate measures tells you little about years of use, about what happens after stopping, or about hard outcomes such as cardiovascular events.

References

Keep reading

Start with the overview, or go deeper on the hormone behind the class.

What is retatrutide?What is GLP-1?All articles